Introducing a breakthrough known as 'CT1812'

Ocrevus (ocrelizumab) was approved in the US by the FDA in March 2017 for the treatment of adults with relapsing or primary progressive forms of MS, based on three clinical trials.

As we await the arrival of edaravone to US pharmacies, patients can access edaravone now through TheSocialMedwork.

With recent drops in new HIV diagnoses being linked to buying PrEP through online buyers clubs, the addition of PrEP to the WHO's essential medicine list, and the recent approval of generic PrEP in the US - here’s what you need to know.

PTC Therapeutics announce the launch of Emflaza for the treatment of Duchenne muscular dystrophy (DMD) within the coming weeks, with an expected net price of $35,000.

What are the results from the clinical studies that led to the approval of edaravone, and how can patients access it in their country?

For the first time in 22 years, the US Food and Drug Administration (FDA) has approved a drug to treat patients with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease; a motor neuron disease characterised by muscular atrophy and weakness.

The latest events surrounding the pricing of a Duchenne muscular dystrophy (DMD) treatment

The PBS, Australia’s national program responsible for providing subsidised prescriptions, has announced the addition of several new medicines

Promising Results from Multiple Studies

The FDA approval of a promising new drug is offering new hope to multiple myeloma patients who have already been through various treatments. 

A new treatment that targets a specific type of lung cancer has received FDA approval. 

On Sunday former US president and Nobel Peace Prize laureate proclaimed to a Sunday school class that he is cancer-free.

The Pharmaceutical and Medical Device Agency (PMDA), has granted marketing approval for the use of Edaravone for the treatment of ALS in Japan.

Impressive results have been published last week regarding two new immunotherapies.